litlas
Log inCreate account

Robert C. Doebele

Active 1994–2025

113
Papers
29,291
Citations
74
h-index
112
i10-index

Citations

Citations per year for Robert C. Doebele1971: 1 citations1996: 3 citations1998: 6 citations1999: 3 citations2000: 5 citations2001: 2 citations2002: 6 citations2003: 2 citations2004: 7 citations2005: 9 citations2006: 6 citations2007: 3 citations2008: 1 citations2009: 2 citations2010: 5 citations2011: 28 citations2012: 107 citations2013: 170 citations2014: 163 citations2015: 232 citations2016: 292 citations2017: 315 citations2018: 423 citations2019: 1,443 citations2020: 1,837 citations2021: 1,729 citations2022: 1,409 citations2023: 896 citations2024: 1,272 citations2025: 600 citations2026: 18 citations1972–1995: no citations, so these years are not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,947 citing papers, 25.3% of this breakdownChina: 1,644 citing papers, 14.1% of this breakdownItaly: 739 citing papers, 6.3% of this breakdownUnited Kingdom: 559 citing papers, 4.8% of this breakdownGermany: 545 citing papers, 4.7% of this breakdownJapan: 535 citing papers, 4.6% of this breakdownFrance: 498 citing papers, 4.3% of this breakdownCanada: 391 citing papers, 3.4% of this breakdownSpain: 386 citing papers, 3.3% of this breakdownSwitzerland: 341 citing papers, 2.9% of this breakdownNetherlands: 306 citing papers, 2.6% of this breakdownSouth Korea: 297 citing papers, 2.5% of this breakdown
0%25.3%Other 21.2%

Institutions

Fields

  • Medicine72.8%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology2.1%
  • Chemistry0.7%
  • Computer Science0.6%
  • Physics and Astronomy0.5%
  • Other2%

Topics

  • Lung Cancer Treatments and Mutations14.7%
  • Cancer Genomics and Diagnostics6.4%
  • Lung Cancer Research Studies6.3%
  • Lung Cancer Diagnosis and Treatment5.4%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Colorectal Cancer Treatments and Studies1.9%
  • Other60.5%

Coauthors

All papers

Open in search
  1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Authors: Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri - The Lancet Oncology 2019 cited by 1,744

  2. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Authors: Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alberto S. Pappo, Brian Turpin, Afshin Dowlati, Marcia S. Brose, Leo Mascarenhas, Noah Federman, Jordan Berlin, Wafik S. El‐Deiry, Christina S. Baik, John F. Deeken, Valentina Boni, Ramamoorthy Nagasubramanian, Matthew H. Taylor, Erin R. Rudzinski, Funda Meric‐Bernstam, Davendra Sohal, C. Patrick, Luis E. Raez, Jaclyn F. Hechtman, Ryma Benayed, Marc Ladanyi, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman - New England Journal of Medicine 2018 cited by 2,728

  3. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

    Authors: Ashley Maynard, Caroline E. McCoach, Julia Rotow, Lincoln Harris, Franziska Haderk, D. Lucas Kerr, Elizabeth A. Yu, Erin L. Schenk, Weilun Tan, Alexander Zee, Michelle Tan, Philippe Gui, Tasha Lea, Wei Wu, Anatoly Urisman, Kirk D. Jones, Rene Sit, K. Kolli, Eric J. Seeley, Yaron Gesthalter, Daniel D. Le, Kevin A. Yamauchi, David M. Naeger, Sourav Bandyopadhyay, Khyati N. Shah, Lauren Čech, Nicholas J. Thomas, Anshal Gupta, Mayra Gonzalez, Hien Do, Lisa Tan, Bianca Bacaltos, Rafael Gómez-Sjöberg, Matthew A. Gubens, Thierry Jahan, Johannes R. Kratz, David M. Jablons, Norma Neff, Robert C. Doebele, Jonathan S. Weissman, Collin M. Blakely, Spyros Darmanis, Trever G. Bivona - Cell 2020 cited by 722

  4. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

    Authors: Daniel R. Gomez, Chad Tang, Jianjun Zhang, George R. Blumenschein, Mike Hernández, J. Jack Lee, Rong Ye, David A. Palma, Alexander V. Louie, D. Ross Camidge, Robert C. Doebele, Ferdinandos Skoulidis, Laurie E. Gaspar, James W. Welsh, Don L. Gibbons, José A. Karam, Brian D. Kavanagh, Anne S. Tsao, Boris Sepesi, Stephen G. Swisher, John V. Heymach - Journal of Clinical Oncology 2019 cited by 1,270

  5. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    Authors: Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah - The Lancet Oncology 2021 cited by 443

  6. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Authors: Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2014 cited by 1,993

  7. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Authors: Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho, Dong‐Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung‐Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. C. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw - Cancer Discovery 2018 cited by 480

  8. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Authors: Daniel R. Gomez, George R. Blumenschein, J Jack Lee, Mike Hernández, Rong Ye, D. Ross Camidge, Robert C. Doebele, Ferdinandos Skoulidis, Laurie E. Gaspar, Don L. Gibbons, José A. Karam, Brian D. Kavanagh, Chad Tang, Ritsuko Komaki, Alexander V. Louie, David A. Palma, Anne S. Tsao, Boris Sepesi, William N. William, Jianjun Zhang, Qiuling Shi, Xin Shelley Wang, Stephen G. Swisher, John V. Heymach - The Lancet Oncology 2016 cited by 1,086

  9. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Authors: Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R. Patel, Chao‐Hua Chiu, Thomas John, Kōichi Goto, Christos S. Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu Li, Young Kwang Chae, Christine H. Chung, Gregory A. Otterson, Haruyasu Murakami, Chia‐Chi Lin, Daniel Shao-Weng Tan, Hans Prenen, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele - The Lancet Oncology 2019 cited by 537

  10. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

    Authors: D. Ross Camidge, Robert C. Doebele, Keith M. Kerr - Nature Reviews Clinical Oncology 2019 cited by 559

  11. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

    Authors: Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou, Manish R. Patel, Myung‐Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert C. Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore‐Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann Johnson, Rupal Patel, David Luo, Edna Chow‐Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo de Braud - Cancer Discovery 2017 cited by 817

  12. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Authors: Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada‐Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Brahmer, Mehmet Altan, Charles Lu, Vassiliki A. Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok‐Kin Wong, John V. Heymach - Nature Medicine 2018 cited by 455

  13. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, M.C. Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2017 cited by 1,325

  14. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

    Authors: Alexander Drilon, Chao‐Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lü, Myung‐Ju Ahn, Matthew Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S.W. Tan, Tejas Patil, Rafał Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena - JTO Clinical and Research Reports 2022 cited by 113

  15. TRKing Down an Old Oncogene in a New Era of Targeted Therapy

    Authors: Aria Vaishnavi, Anh‐Tuan Le, Robert C. Doebele - Cancer Discovery 2014 cited by 644

  16. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

    Authors: Collin M. Blakely, Thomas B.K. Watkins, Wei Wu, Beatrice Gini, Jacob J. Chabon, Caroline E. McCoach, Nicholas McGranahan, Gareth A. Wilson, Nicolai J. Birkbak, Victor Olivas, Julia Rotow, Ashley Maynard, Victoria Wang, Matthew A. Gubens, Kimberly C. Banks, Richard B. Lanman, Aleah F. Caulin, John St. John, Anibal R. Cordero, Petros Giannikopoulos, Andrew D. Simmons, Philip C. Mack, David R. Gandara, Hatim Husain, Robert C. Doebele, Jonathan W. Riess, Maximilian Diehn, Charles Swanton, Trever G. Bivona - Nature Genetics 2017 cited by 578

  17. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

    Authors: Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz, Amy Weise, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G. Tirunagaru, Feng Xu, Robert C. Doebele, David S. Hong - Journal of Clinical Oncology 2023 cited by 91

  18. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

    Authors: Tejas Patil, Derek Smith, Paul A. Bunn, Dara L. Aisner, Anh T. Le, Mark J. Hancock, W. Thomas Purcell, Daniel W. Bowles, D. Ross Camidge, Robert C. Doebele - Journal of Thoracic Oncology 2018 cited by 199

  19. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

    Authors: Andrew Weickhardt, Benjamin Scheier, Joseph Burke, Gregory N. Gan, Xian Lu, Paul A. Bunn, Dara L. Aisner, Laurie E. Gaspar, Brian D. Kavanagh, Robert C. Doebele, D. Ross Camidge - Journal of Thoracic Oncology 2012 cited by 677

  20. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: Rafał Dziadziuszko, Matthew Krebs, Filippo de Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish Patel, Byoung Chul Cho, Stephen V. Liu, Myung‐Ju Ahn, Chao‐Hua Chiu, Anna F. Farago, Chia‐Chi Lin, Christos S. Karapetis, Yu Li, Bann‐Mo Day, David Chen, Timothy R. Wilson, Fabrice Barlési - Journal of Clinical Oncology 2021 cited by 156

  21. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

    Authors: Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella‐Garcia, Robert C. Doebele - Clinical Cancer Research 2012 cited by 472

  22. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

    Authors: Y. Wang, Tao Jiang, Zhen Qin, Jinghui Jiang, Qiang Wang, Seung Hee Yang, Christopher J. Rivard, G. Gao, Tony L. Ng, Megan M. Tu, Hui Yu, Huiping Ji, Caicun Zhou, Shengxiang Ren, Jun Zhang, Paul A. Bunn, Robert C. Doebele, D. Ross Camidge, Fred R. Hirsch - Annals of Oncology 1999 cited by 217

  23. Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer

    Authors: Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth A. Jones, Laura Schubert, Andrea E. Doak, Adriana Estrada‐Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, W. Tom Purcell, Rafał Dziadziuszko, Marileila Varella‐Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele - Clinical Cancer Research 2018 cited by 246

  24. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

    Authors: David S. Hong, Todd M. Bauer, J.J. Lee, Afshin Dowlati, Marcia S. Brose, Anna F. Farago, Matthew H. Taylor, Alice T. Shaw, Sandra Montez, Funda Meric‐Bernstam, Steven G. Smith, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, M.C. Cox, Howard A. Burris, Robert C. Doebele - Annals of Oncology 2019 cited by 153